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Abstract Bemfola (follitropin alfa) (Finox AG, Switzerland), a new recombinant FSH, has a comparable pharmacological proﬁle to
that of Gonal-f (Merck Serono, Germany), the current standard for ovarian stimulation. A randomized, multi-centre, Phase 3 study
in women undergoing IVF or intracytoplasmic sperm injection (n = 372) showed Bemfola yielding similar efﬁcacy and safety proﬁles
to Gonal-f. Women aged 20–38 years of age were randomized 2:1 to receive a single, daily, subcutaneous 150 IU dose of either Bemfola
or Gonal-f. This study tested equivalence in the number of retrieved oocytes using a pre-determined clinical equivalence margin of
±2.9 oocytes. Compared with Gonal-f, Bemfola treatment resulted in a statistically equivalent number of retrieved oocytes (Bemfola
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10.8 ± 5.11 versus Gonal-f 10.6 ± 6.06, mean difference: 0.27 oocytes, 95% conﬁdence interval: −1.34, 1.32) as well as a similar clini-
cal pregnancy rate per embryo transfer in ﬁrst and second cycles (Bemfola: 40.2% and 38.5%, respectively; Gonal-f: 48.2% and 27.8%,
respectively). No difference in severe ovarian hyperstimulation syndrome was observed between treatment groups (Bemfola: 0.8%;
Gonal-f: 0.8%). This study demonstrates similar clinical efﬁcacy and safety proﬁles between Bemfola and Gonal-f, and suggests that
Bemfola can be an appropriate alternative in ovarian stimulation protocols.
© 2015 The Authors. Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
The recombinant FSH (r-FSH) preparations Gonal-f (Merck
Serono, Darmstadt, Germany) and Puregon have been com-
mercially available since 1995 and 1996, respectively
(Lunenfeld, 2004). Recently, biosimilar versions of r-FSH have
been developed to provide high quality but economically at-
tractive alternatives to the present FSH products.
For treating infertility, Gonal-f (Merck Serono, Germany)
is used in the following indications: ovulation induction with
human FSH in normogonadotrophic (World Health Organiza-
tion [WHO] type II) anovulatory women; ovulation induction
in WHO type I anovulatory infertility in association with a LH
preparation; and ovarian stimulation in patients undergoing
assisted reproduction technique treatment or in milder forms
of intrauterine insemination. It has been recognized that the
high treatment costs restrict access to high-quality biologi-
cal medicines (Engelberg et al., 2009; Schellekens and Moors,
2010). ‘Biosimilar’ medicines, which are medical products
whose active drug substance is made by or derived from a living
organism by recombinant DNA or controlled gene expres-
sion, meet high standards for comparability to the origina-
tor medicine and are approved for use in the same indications
(Weise et al., 2012).
Bemfola (Finox AG, Switzerland) is the ﬁrst r-FSH biosimilar
on the market that has been demonstrated to have similar
physicochemical properties in pre-clinical studies and is in-
tended for use in the same therapeutic indications as Gonal-f
(Merck Serono, Germany). Bemfola (Finox AG, Switzerland)
has similar non-clinical pharmacological, pharmacokinetic and
toxicological proﬁles to those of Gonal-f (Merck Serono,
Germany) (European Public Assessment Report, Bemfola,
(European Medicines Agency, 2014)). An important differ-
ence between the two products is that Bemfola (Finox AG,
Switzerland) does not contain m-cresol as an excipient because
Bemfola (Finox AG, Switzerland) is presented as a single-
use injection system with no required preservative. In con-
trast, the Gonal-f injection device (Merck Serono, Germany)
is for multiple use and includes preservatives in the formu-
lation. The Bemfola pen (Finox AG, Switzerland) offers a ﬁne-
tuned dosing scheme of a minimum of 12.5-IU increments.
Other characteristics of the single-use pen are volume and
injection-control mechanisms and visual aids that may improve
treatment compliance. Additionally, an in-built lock pre-
vents re-use of the pen device by the patient.
The objective of this study was to demonstrate the equiva-
lence of Bemfola (Finox AG, Switzerland) and the compara-
tor product Gonal-f (Merck Serono, Germany) in ovarian
stimulation for IVF or intracytoplasmic sperm injection (ICSI).
Because of the similarity in the active substance as well as
the formulation, Bemfola treatment (Finox AG, Switzer-
land) was expected to result in efﬁcacy and safety proﬁles
similar to those of Gonal-f (Merck Serono, Germany). This ex-
pectation was based on results from a Phase 1 clinical trial,
FIN1001, which demonstrated equivalent pharmacokinetic pro-
ﬁles between Bemfola (Finox AG, Switzerland) and Gonal-f
(Merck Serono, Germany). Bemfola (Finox AG, Switzerland)
was designed to be a biosimilar of Gonal-f (Merck Serono,
Germany), thereby showing familiar efﬁcacy and safety pro-
ﬁles compared with Gonal-f (Merck Serono, Germany).
Materials and methods
Study FIN3001 was an assessor-blinded, randomized, parallel-
group, multi-centre, Phase 3 trial conducted in women un-
dergoing assisted reproduction techniques (n = 372), who were
treated with a ﬁxed-dose regimen of a daily, single subcu-
taneous dose of 150 IU Bemfola (Finox AG, Switzerland) or
150 IU Gonal-f (Merck Serono, Germany). A total of 15 centres
in six European countries received study medication and re-
cruited eligible patients into the study: the participating coun-
tries (number of centres) were Austria (n = 5), Denmark
(n = 3), Germany (n = 2), Spain (n = 2), Switzerland (n = 1)
and UK (n = 2). The study was conducted between July 2010
and April 2012, with a consecutive pregnancy follow-up period.
The study was registered in clinicaltrials.gov (NCT01121666).
To test immunogenicity, patients who did not become preg-
nant after a completed cycle of recombinant human FSH (r-
hFSH) treatment and IVF or ICSI had the option of undergoing
a second cycle of r-hFSH treatment at least 4 weeks after ter-
mination of the ﬁrst treatment cycle; patients remained al-
located to the study group arm Bemfola (Finox AG,
Switzerland) or Gonal-f (Merck Serono, Germany), respec-
tively. The schedule of assessment and follow-up proce-
dures were according to the main study. The study was
primarily powered for the ﬁrst treatment cycle but not for
the second treatment cycle, which was carried out to evalu-
ate anti-FSH antibodies based on repeated administration of
FSH as agreed upon by the European Medicinal Agency (EMA);
as a consequence, only descriptive analysis was conducted for
the second treatment cycle. Numbers presented in the present
study reﬂect the full data of the ﬁrst treatment cycle, in-
cluding immunogenicity data and the pregnancy rates of the
second treatment cycle.
The study was approved by the Independent Medical Ethics
Committee or Institutional Review Board of respective coun-
tries and was conducted in accordance with Good Clinical Prac-
tice, Declaration of Helsinki, the International Conference on
Harmonisation guidelines for Good Clinical Practice CHMP/
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ICH/135/95, and local regulatory requirements/laws. The
aims, methods, anticipated beneﬁts and potential hazards of
the study were expained to all participants, and written in-
formed consent was obtained from each.
Study population
Women who fulﬁlled the following inclusion criteria were eli-
gible: age between 20 and 38 years; body mass index (BMI)
between 18 and 30 kg/m2; regular menstrual cycles of 25–
35 days; and ﬁrst or second cycle in the present series of as-
sisted reproduction techiques. Other key inclusion criteria were
basal FSH less than 10 IU/L (cycle day 2–5); oestradiol levels
less than 50 pg/mL on the ﬁrst day of FSH administration; a
total antral follicle count of 10–25 follicles; infertility re-
sulting from tubal factors; mild endometriosis (American
Society of Reproductive Medicine [ASRM] stage 1–2 (American
Society for Reproductive Medicine (ASRM), 1997); male factor;
unexplained infertility; and presence of both ovaries and
normal uterine cavity as conﬁrmed by transvaginal ultra-
sound within 6 months before randomization. Key exclusion
criteria were a history of more than two earlier assisted re-
production technique retrieval cycles; the presence of en-
docrine disorder; known tumours of the hypothalamus and
pituitary gland, or both; a history of severe ovarian hyper-
stimulation syndrome (OHSS); severe endometriosis (ASRM
stage 3 or 4) (American Society for Reproductive Medicine
(ASRM), 1997); the presence of a hydrosalpinx; polycystic
ovaries (Rotterdam ESHRE/ASRM-Sponsored PCOS consensus
workshop group, 2004); history of poor response to gonado-
trophin treatment (deﬁned as fewer than ﬁve oocytes re-
trieved in a previous attempt); and any hormonal treatment
within 1 month before starting FSH treatment (with the ex-
ception of levothyroxin).
Study design
The goal of this assessor-blinded, randomized, parallel-
group, multi-centre study was to compare the efﬁcacy and
safety proﬁles of Bemfola (Finox AG, Switzerland) with those
of Gonal-f (Merck Serono, Germany) after daily administra-
tion of 150 IU. This ﬁxed daily dose (150 IU FSH/day) design
was based on the Scientiﬁc Advice provided by the EMA in 2008
and used to reduce inter-group variability that might occur
if different investigator-initiated dosing schemes had been
applied. Eligible participants were randomized in a 2:1 ratio
to receive either Bemfola (Finox AG, Switzerland) or Gonal-f
(Merck Serono, Germany), respectively. Patient randomiza-
tion into the two treatment groups was also stratiﬁed by age
(<35 and ≥35 years). Centralized treatment allocation with
an interactive web response system was used and ﬁled in the
study centre ﬁle. A minimization algorithmwas used to achieve
an optimally balanced patient allocation, overall and across
the strata. The outcome of pregnancies was followed up within
the context of safety follow-up information.
Treatment administration
All eligible participants were down-regulated with a
gonadotrophin-releasing hormone (GnRH) agonist initiated in
the luteal phase. The GnRH agonists triptorelin (Ipsen, France),
buserelin (Sanoﬁ-Aventis, Germany) and leuprorelin (Sandoz,
Switzerland), were subcutaneously administered according to
local practice. After successful down-regulation with an oes-
tradiol level of less than 50 pg/mL, a shedded endometrium
thickness of less than 5 mm and no ovarian cysts, partici-
pants were randomized 2:1 to receive either Bemfola (Finox
AG, Switzerland) or Gonal-f (Merck Serono, Germany) at a dose
of 150 IU/day (Figure 1); FSH in both groups was adminis-
tered subcutaneously. After 6 days of FSH administration and
only in cases of risk of OHSS or other safety concerns, could
the ﬁxed daily 150 IU FSH dose be decreased, coasting applied
or treatment terminated. Once at least one follicle reached
a diameter of 18 mm or over and two additional follicles
reached a diameter of 16 mm or over, a dose of 250 µg r-hCG
(Ovitrelle; Merck Serono, Germany) was given to trigger ovu-
lation and 34–36 h later, oocytes were retrieved. If the cri-
teria for ovulation triggering could not be reached by FSH
stimulation on day 16, treatment was to be stopped. Both ICSI
and IVF were carried out according to the centre’s standard
procedures, and a maximum of two embryos or blastocysts
were transferred 2–5 days after oocyte retrieval.
Assessments
Ovarian response was assessed by vaginal ultrasound at base-
line, at days 6 and 8, and on the day of human chorionic
agonist treatment
Continuation GnRH
Confirmation of 
down-regulation
Cycle
Day 2–5 Day 21
Down-reglation
Day 1
of FSH
GnRH-agonist
150 IU per day
Day of
HCG/oocyte 
retrieval
Embryo 
transfer
Post-oocyte
retrieval phase
Clinical 
Pregnancy
Biochemical
pregnancy
Figure 1 Study design.
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gonadotrophin (HCG) administration for a maximum of
16 days after the start of treatment with r-hFSH. For the
purpose of subject safety, serum oestradiol concentration
was measured as well. After day 8, follicular development
was monitored by vaginal ultrasound at 2- to 3-day inter-
vals. The vaginal ultrasound assessor and the investigator
were blinded regarding the r-hFSH preparation of the patient.
Surplus pronuclear stages or embryos were cryopreserved
according to local regulations. Further safety follow-up visits
were scheduled. The pregnancy rate was determined bio-
chemically (i.e. about 2 weeks after oocyte retrieval), and,
clinically, (i.e. 5–6 weeks after oocyte retrieval), respec-
tively. Clinical pregnancy was deﬁned as the presence of at
least one intrauterine gestational sac. Utrogestan (Besins
Healthcare, Belgium) was vaginally administered and used for
luteal support at a concentration of 3 × 200 mg per day be-
ginning at the day of embryo or blastocyst transfer until con-
ﬁrmation of clinical pregnancy. A blood sample was taken for
anti-Müllerian Hormone (AMH) determination at the base-
line visit (day of the start of FSH treatment). Processed blood
samples were sent to a central laboratory where they were
measured, after the study was completed, with the AMH
Gen II enzyme linked immunosorbent assay test kit of
Beckman-Coulter.
Immune response was investigated using a validated
surface plasmon resonance method, an immunoassay
method using adsorption properties of possible antibodies to
FSH bound to speciﬁc platelets (Szolar et al., 2007). At base-
line, 3 weeks and 8 weeks after completing the FSH
treatment in both treatment cycles, blood samples were
taken to detect possible anti-FSH antibodies. In case
anti-FSH antibodies were detected, further conﬁrmation assays
were run to characterize the cross-reactivity to other
proteins sharing the common alpha chain with FSH and the
neutralization potential of such antibodies. Patients in both
treatment arms who did not become pregnant in the ﬁrst
treatment cycle, and who underwent an additional
assisted reproduction technique cycle, were investigated for
potential immunogenicity after repeated treatment cycles.
Surface plasmon resonance method, an immunoassay detect-
ing and characterizing possible antibodies by binding to FSH
bound to speciﬁc platelets was used to detect anti-FSH an-
tibodies expressed in relative units (relU). The cut-off point
for a positive response, which is a certain signal above the
serum background of untreated serum samples, was set to 104
relU; above this value, a serum sample was regarded as a ‘posi-
tive hit’, and a subsequent conﬁrmation assay was there-
fore required.
End-points
The primary end-point was the number of oocytes retrieved.
Secondary end-points included the quality of oocytes re-
trieved; fertilization rate of oocytes; embryo quality; number
of cryopreserved pronuclear stages, embryos or blastocysts;
total dose of r-hFSH required; number of days of r-hFSH stimu-
lation; number of patients with cycle cancellation owing to
excessive response and low response. Adverse events were
recorded as secondary safety end-points. Pharmacodynami-
cally, the number and size of follicles 12 mm or over in diamter
at day 8 of stimulation as well as on the day of HCG admin-
istration were evaluated as secondary end-points. Other sec-
ondary end-points included implantation and clinical pregnancy
rates, ongoing pregnancy and live birth rate.
Statistical methods
This study was powered to test equivalence using a two
one-sided test (TOST) of the primary end-point (i.e. the
number of oocytes retrieved) with a power of 90%, an
alpha error of 2.5% and a pre-determined clinical
equivalence margin of ±2.9 oocytes for the relevant popula-
tion. Because of the non-normality of the distribution of
the primary end-point, which was proven by the Shapiro-
Wilk test, a Mann-Whitney U test was carried out in both
populations. A poor responder rate of 5% was included. A
sample size of 351 patients with a 2:1 ratio (234/117) was
calculated under the hypothesis (±2.9 is the considered
clinical equivalence margin for the mean difference): H0:
Δ < −2.9 or Δ > 2.9 null hypothesis; H1: −2.9 ≤ Δ ≤ 2.9 alter-
native hypothesis. The corresponding 95% conﬁdence inter-
val was approximated by a bootstrap-t approach. Schuirmann’s
TOST test was carried out to conﬁrm the robustness of the
results. Analyses of covariance stratiﬁed by demographic
and baseline characteristics were used to investigate the
treatment effects of (Bemfola Finox AG, Switzerland) and
Gonal-f (Merck Serono, Germany) on number of oocytes re-
trieved. The primary efﬁcacy analysis was based on the per-
protocol populations. The analysis of adverse events,
laboratory data, vital signs, physical examination ﬁndings and
other safety evaluations was carried out on the intention-to-
treat (ITT) population, which included all patients who re-
ceived any amount of study drug. P < 0.05 was considered
statistically signiﬁcant.
Results
A total of 460 patients were enrolled in this trial; 88 pa-
tients were reported as screening failures (Figure 2). A total
of 372 patients were randomized whereas 39 randomized
patients were excluded from the per-protocol population
because of protocol deviations. Therefore, a total of 333 pa-
tients were analysed in the per-protocol population (i.e. 220
patients in the Bemfola group and 113 patients in the Gonal-f
group).
Most patients (>75%) were younger than 35 years of age,
and over 90% of patients were white (Table 1). No appre-
ciable differences were observed in baseline FSH concentra-
tion, antral follicle count, and GnRH agonist duration.
Subsequent evaluation of the AMH level, however, revealed
that, although a higher percentage of patients treated with
Bemfola (Finox AG, Switzerland) had an AMH level of
≥24 pmol/L compared with those on Gonal-f treatment (Merck
Serono, Germany) (42.6% versus 38.2%, respectively), the dif-
ference between treatment groups was not statistically sig-
niﬁcant (Table 1). The cut-off level of ≥24 pmol/L was deﬁned
on the basis of the evaluated level by Lee et al. (2008), and
was applied as the suggested cut-off level for this study to
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evaluate potential high-responder patients in both treat-
ment groups.
Primary end-point: number of retrieved
oocytes from patients undergoing assisted
reproduction techniques
Bemfola (Finox AG, Switzerland) treatment resulted in a
number of oocytes statistically equivalent to that of pa-
tients treated with Gonal-f (Merck Serono, Germany) (Table 2).
The treatment difference was 0.27 oocytes (95% conﬁdence
interval: −1.34, 1.32) yielding a P-value for equivalence of
P = 0.0003, demonstrating equivalence as pre-deﬁned in the
statistical analysis plan (less than three oocytes). The results
from ITT analysis was similar to the data showed from per pro-
tocol analysis, thereby conﬁrming the observed equivalence
between Bemfola (Finox AG, Switzerland) and Gonal-f (Merck
Serono, Germany).
Evaluation of FSH stimulation phase
No signiﬁcant difference was observed in the total dose of
r-hFSH administered between participants treated with
Bemfola compared with those in the Gonal-f treatment group
(P = 0.9638), and in mean duration of stimulation between
both treatment arms (P = 0.8926) (Table 1). Participants
treated with Bemfola (Finox AG, Switzerland) were re-
ported with comparable numbers of follicles 12 mm or over,
15 mm or over, and 17 mm or over compared with those in
the Gonal-f (Merck Serono, Germany) group (P = 0.2357,
0.1395, and 0.3992, respectively). The concentration of oes-
tradiol was also comparable in patients treated with Bemfola
(Finox AG, Switzerland) and Gonal-f (Merck Serono, Germany)
on day of HCG administration (Table 1).
Assessment of response and oocyte quality
Most patients (>90%) in both treatment arms were reported
with an oocyte retrieval of four or more oocytes (Table 2).
The percentage of oocytes with a high degree of cumulus
oophorus maturity (i.e. ‘very mature’) was similar in both
groups, but was lower than that reported for mature oocytes;
this was also the case in the percentage of immature oocytes.
Most oocytes in both treatment groups were in the metaphase-
II stage of nuclear development, and no signiﬁcant differ-
ence in the fertilization rate was observed between treatment
arms.
Bemfola (Finox AG, Switzerland) treatment resulted in a
similar number of patients with embryo transfer and
cryopreservation compared with those receiving Gonal-f (Merck
Serono, Germany) (Table 2). The main embryo quality pa-
rameters observed (i.e. mean number of blastomeres and the
absence of multinucleation) were similar in both groups.
Bemfola
(n = 249)
Gonal-f
(n = 123)
Enrolment
(n = 460)
Randomized
(n = 372)
Screening failures (n = 88)
 •  Not meeting inclusion criteria (n = 21)
 •  Declined to participate (n = 7)
 •  Other reasons (n = 60)
Protocol Deviation (n = 10)
 •  Not meeting inclusion
     criteria (n = 2)
 •  Inaccurately completed
     assessment forms (n = 2)
 •  Termination during treatment
     (n = 3)
 •  End-point not reached (n = 2)
 •  After treatment deviations
     (n = 1)
Protocol Deviation (n = 29)
 •  Not meeting inclusion criteria
     (n = 7)
 •  Inaccurately completed
     assessment forms (n = 9)
 •  Termination during treatment
     (n = 7)
 •  End-point not reached (n = 1)
 •  After treatment deviations
     (n = 3)
 •  Treated not as randomized
     (n = 2)
Per protocol
Population (n = 220)
Per protocol
Population (n = 113)
Figure 2 Patient disposition scheme.
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Implantation rate and pregnancy outcome per
embryo transferred
Treatment cycle 1 resulted in an implantation rate for Bemfola
(Finox AG, Switzerland) that was similar to that reported for
Gonal-f (Merck Serono, Germany) (Bemfola: 31.8%; Gonal-f:
36.7%) (Table 2). Biochemical and clinical pregnancy rates
were also similar between treatment groups. The percent-
ages of patients with an ongoing pregnancy and live born chil-
dren did not reveal any signiﬁcant differences between both
treatments groups. The mean number of transferred embryos
and blastocysts was slightly higher in the Gonal-f (Merck
Serono, Germany) group compared with the Bemfola (Finox
AG, Switzerland) group, with a trend towards a higher number
of blastocysts transferred in the Gonal-f (Merck Serono,
Germany) group (Table 2).
Only results of treatment cycle 2 on the clinical and
ongoing pregnancy rate (Table 2) and the repeated tests
for immunogenicity are shown (Table 3). In contrast to
data from treatment cycle 1, the clinical pregnancy
rate for Bemfola (Finox AG, Switzerland) and Gonal-f (Merck
Serono, Germany) evaluated from treatment cycle 2 was,
although not signiﬁcant, higher in the Bemfola (Finox AG,
Switzerland) group compared with the Gonal-f (Merck
Serono, Germany) group. With the ongoing pregnancy
rate, the same non-signiﬁcant difference in favour of
Bemfola (Finox AG, Switzerland) could be reported
(Table 2).
Adverse event proﬁle
The adverse effects in patients treated with Bemfola (Finox
AG, Switzerland) were relatively similar to that observed in
Gonal-f (Merck Serono, Germany) patients. The most com-
monly reported adverse reactions reported in both study arms
Table 1 Demographic characteristics and assessment of stimulation phase.
Bemfola Gonal-f
n = 249 n = 123
Demographic characteristics
Age (±SD), years 31.8 (4.03) 32.1 (3.76)
BMI (±SD), kg/m2 22.7 (2.88) 22.4 (2.56)
Race, n (%)
White 226 (91.9) 117 (95.1)
Asian 12 (4.9) 3 (2.4)
African 2 (0.8) 1 (0.8)
Other 6 (2.4) 2 (1.6)
FSH baseline concentration (IU/L) 6.9 (1.50) 6.9 (1.56)
Antral follicle count (mean SD) 15.1 (3.77) 15.3 (3.83)
GnRH-agonist duration (days; mean SD) 23.5 (7.92) 22.7 (7.46)
AMH ≥ 24 pmol/L, n (%) 106 (42.6) 47 (38.2)
Assessment of stimulation phase
Mean total dose of r-hFSH (SD) IU 1555.7 (293.00) 1569.2 (259.20)
Duration of FSH medication (SD) days 10.6 (1.91) 10.7 (1.72)
Number of follicles (SD)
≥12 mm 11.8 (4.73) 11.1 (4.23)
≥15 mm 8.3 (3.81) 7.7 (3.60)
≥17 mm 4.9 (3.29) 4.5 (2.71)
Oestradiol serum concentrations (SD), pmol/L
Day of HCG 8982.3 (6535.3) 7704.2 (5345.8)
Day 8 3958.9 (3699.4) 3234.0 (2428.1)
Safety assessment
OHSS, n (%) 14 (5.6) 4 (3.3)
Patients with OHSS and AMH ≥ 24 pmol/L 8 (57.1) 1 (25.0)
Patients with dose reduction due to risk of
hyperstimulation, n (%)
38 (15.3) 16 (13.0)
Patients with coasting due to risk of
hyperstimulation, n (%)
3 (1.2) 3 (2.4)
Patients with hCG withdrawal due to
risk of hyperstimulation, (n, %)
5 (2.0) 1 (0.8)
Numbers are mean (SD) values unless otherwise indicated.
Differences in each of the parameters were not statistically signiﬁcant.
AMH = anti-Müllerian hormone; BMI = body mass index; GnRH = gonadotrophin-releasing hormone;
OHSS = ovarian hyperstimulation syndrome; r-hFSH = recombinant FSH; SD = standard
deviation.
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were headache, ovarian cysts and local injection site
reactions (e.g. pain, erythema, haematoma, swelling, irri-
tation, or both, at the site of injection) (data not shown). All
grades of OHSS were reported in 5.6% of the patients in the
Bemfola (Finox AG, Switzerland) group and in 3.3% of the
patients in the Gonal-f (Merck Serono, Germany) group
(P = 0.4428), whereas severe OHSS (The Practice Committee
of the American Society for Reproductive Medicine, 2004), oc-
curred in less than 1% of patients in either study arm (0.8%
in both treatment groups). Eight out of 14 patients with re-
ported OHSS in the Bemfola (Finox AG, Switzerland) group had
an AMH level of 24 pmol/L or over compared with one out of
four patients in the Gonal-f (Merck Serono, Germany) group
(Table 1).
Immunogenicity proﬁle
Analysis of antibodies speciﬁc for Bemfola (Finox AG,
Switzerland) or Gonal-f (Merck Serono, Germany) in-
dicated no evidence of immunogenicity (i.e. antibody
reactivity to Bemfola or Gonal-f) in either treatment
group during both treatment cycles. All patients had anti-
follitropin antibody levels below the serum background of
untreated serum samples at baseline in both treatment
cycles (Table 3). No patient showed any increase in re-
sponse units, as measured 3 and 8 weeks after completion of
FSH treatment. This was also the case for patients being re-
treated with the same FSH preparation in the second treat-
ment cycle.
Table 2 Number and quality of retrieved oocytes, secondary efﬁcacy parameters, and clinical efﬁcacy outcome.
Bemfola EU-Gonal-f Treatment
difference
P-value
Per protocol population (patients with oocyte
retrieval after completed treatment cycle)
n = 220 n = 113
Number of oocytes retrieved ± SD 10.8 ± 5.11 10.6 ± 6.06 0.27 (−1.34, 1.32) 0.0003a
Intention-to-treat population n = 249 n = 123
Number of oocytes retrieved ± SD 10.7 ± 5.62 10.4 ± 6.14 0.29 (–1.29, 1.34) 0.0003a
Number of embryos/blastocysts transferred (mean ± SD)
Number of patients with transferred embryos, n (%)
1.5 ± 0.52 1.6 ± 0.53
Day 2 82 (32.9) 36 (29.2)
Day 3 53 (21.3) 28 (22.8)
Number of patients with transferred blastocysts, n (%)
Day 4 10 (4.0) 2 (1.6)
Day 5 76 (30.5) 46 (37.4)
Patients with good responseb 225 (90.4) 112 (91.0)
Cycle cancellations 13 (5.2) 5 (4.1)
Cumulus oophorus Maturity, n (%)
Very mature 214 (9.1) 106 (9.4)
Mature 1773 (75.7) 849 (75.3)
Immature 339 (14.5) 160 (14.2)
Nuclear maturity, n (%)
Germinal vesicle 203 (9.5) 92 (9.1)
Metaphase I 154 (7.2) 78 (7.7)
Metaphase II 1788 (83.4) 845 (83.3)
Number of blastomeres at day 3 (mean ± SD) 6.6 ± 2.41 6.4 ± 2.49
Absence of multinucleation at day 3, n (%) 927 of 990 (93.6) 512 of 545 (93.9)
Fertilization rate (mean ± SD) 66.1 ± 24.84 64.0 ± 24.76
Patients with embryo transfer, n (%) 224 (89.9) 114 (92.7)
Patients with cryopreservation, n (%) 103 (41.4) 55 (44.7)
Implantation rate, n (%)c 110 of 346 (31.8) 66 of 180 (36.7)
Biochemical pregnancy rate per embryo transfer, n (%) 116 (51.8) 60 (52.6)
Clinical pregnancy rate per embryo transfer, n (%)d 90 (40.2) 55 (48.2)
Ongoing pregnancy per embryo transfer, n (%)e 84 (37.5) 51 (44.7)
Patients with liveborn children, n (%) 80 (35.7) 50 (43.9)
Second treatment cycle n = 72 n = 38
Clinical pregnancy rate per embryo transfer, n (%)d 25 (38.5) 10 (27.8)
Ongoing pregnancy per embryo transfer, n (%)e 22 (33.8) 9 (25.0)
aP-value indicating a high signiﬁcance for clinical equivalence; differences in remaining parameters are not statistically signiﬁcant.
bPatients with an oocyte retrieval of four or more oocytes.
cDeﬁned as fetal sac per embryo transferred.
dPresence of at least one intrauterine gestational sac.
ePresence of at least one viable fetus 10 weeks after embryo transfer.
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Discussion
This study has shown that Bemfola (Finox AG, Switzerland)
and Gonal-f (Merck Serono, Germany) are statistically equiva-
lent in the primary physiological function of FSH; that is, in
stimulation of follicular development. In addition, Bemfola
(Finox AG, Switzerland) and Gonal-f (Merck Serono, Germany)
seem to have similar efﬁcacy and safety proﬁles. The evalu-
ation of potential biosimilarity between Bemfola (Finox AG,
Switzerland) and Gonal-f (Merck Serono, Germany) was based
on data obtained from an assessor-blinded, randomized,
parallel-group, multi-centre, Phase 3 trial conducted in women
undergoing assisted reproduction techniques. The study design
was chosen to examine the degree of biosimilarity between
both treatments, whereas a 2:1 randomization ratio was in-
tended to allow a more comprehensive assessment of the
safety proﬁle of Bemfola (Finox AG, Switzerland) in this patient
population.
Patients enrolled in this study were representative of
the patient population usually treated in this clinical setting.
The mean age of the patients (abouty 32 years of age),
the proportions of patients above and below 35 years of age,
and the mean BMI (about 23) correspond well to the charac-
teristic general assisted reproduction technique population
documented in the medical literature (Andersen et al., 2006;
Bergh et al., 1997; Frydman et al., 2000; Schats et al., 2000).
Overall, the population for this Phase 3 study met the ex-
pected criteria and was well balanced between the treat-
ment arms. No baseline characteristics could be identiﬁed that
showed variance between the two groups.
To investigate potential immunogenicity, a second treat-
ment cycle for patients who did not become pregnant during
the ﬁrst treatment cycle and who still met the eligibility cri-
teria was offered and performed (if accepted) to evaluate the
possible emergence of anti-FSH antibodies following re-
peated exposure to the same recombinant FSH (either Bemfola
or Gonal-f). Pooling the results from both treatment cycles
was not intended in the statistical analysis, because no re-
randomization was carried out in the second treatment
cycle. Safety and efﬁcacy results for a non-randomized
sub-population would be potentially biased. Therefore,
the data from each treatment cycle must be analysed
independently. The results presented reﬂect the outcome
of the ﬁrst treatment cycle as statistically relevant; the
study was not powered for the detection of statistically rel-
evant differences of any variable in the second treatment
cycle.
The primary end-point for the FIN3001 study was the
number of oocytes retrieved in the relevant per protocol
patient population. The data showed that Bemfola (Finox AG,
Switzerland) administered subcutaneously at a dose of 150 IU
daily was statistically equivalent (within the protocol-
deﬁned equivalence margin) to Gonal-f (Merck Serono,
Germany) in terms of number of retrieved oocytes. The sec-
ondary end-points used in this Phase-3 study are standard end-
points in assisted reproduction technology clinical studies.
Similar results were also observed in secondary efﬁcacy end-
points such as oestradiol levels, number and size of follicles
and pregnancy outcome. The numbers of oocytes retrieved
from patients in this study are similar to those of other studies
of r-FSH in assisted reproduction technologies (Bergh et al.,
1997; Bühler and Naether, 2011; Frydman et al., 2000;
Jayaprakasan et al., 2010; Schats et al., 2000). Although this
study was not powered to detect a difference between treat-
ments for secondary efﬁcacy end-points, the results were con-
sistent with those found in other studies.
The clinical pregnancy outcome as a secondary end-
point of the study was not signiﬁcantly different between
treatment groups in both treatment cycles. Although the study
was not powered to evaluate signiﬁcant differences in clini-
cal pregnancy rate, however, an 8% difference in clinical preg-
nancy rate in favour of Gonal-f (Merck Serono, Germany) in
the ﬁrst treatment cycle and a 10.7% difference in clinical
pregnancy rate in favour of Bemfola (Finox AG, Switzer-
land) in the second treatment cycle was found. In view of there
being slightly more day-5 blastocyst transfers in treatment
cycle 1 in the Gonal-f (Merck Serono, Germany) group com-
pared with the Bemfola (Finox AG, Switzerland) group (37.4%
versus 30.5%), this may have contributed to the non-signiﬁcant
differences in clinical pregnancy and live birth rate in this study
Table 3 Mean anti-follitropin antibody levels (full analysis set).
Actual values (relU)
Treatment group Visit n Mean SD
Treatment cycle 1
Bemfola Baseline 247 42.2 43.87
3 weeks after FSH treatment 219 40.4 43.80
8 weeks after FSH treatment 192 42.2 42.07
Gonal-f Baseline 121 39.6 30.36
3 weeks after FSH treatment 106 39.6 30.47
8 weeks after FSH treatment 114 38.8 29.40
Treatment cycle 2
Bemfola Baseline 72 37.8 30.52
3 weeks after FSH treatment 67 38.6 30.74
8 weeks after FSH treatment 58 41.8 32.17
Gonal-f Baseline 37 35.5 21.55
3 weeks after FSH treatment 33 35.2 22.32
8 weeks after FSH treatment 35 37.9 25.37
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(Table 2). Additional clinical trials are warranted to further
document these end-points.
The biosimilarity between Bemfola (Finox AG, Switzer-
land) and Gonal-f (Merck Serono, Germany) for various efﬁ-
cacy parameters was coupled with a safety proﬁle that is
consistent with other studies in this clinical setting
(Recombinant Human FSH Study Group, 1995; Bergh et al.,
1997; Frydman et al., 2000; Schats et al., 2000; Balen et al.,
2007). In addition, Bemfola (Finox AG, Switzerland) treat-
ment did not result in increased immunogenicity compared
with the reference comparator Gonal-f (Merck Serono,
Germany). Findings were consistent between per protocol and
ITT analysis sets in the ﬁrst treatment cycle, thereby con-
ﬁrming the robustness of the data.
The overall OHSS rate (includingmild,moderate and severe
forms) was 5.6% for Bemfola (Finox AG, Switzerland) and 3.3%
for Gonal-f (Merck Serono, Germany). Severe OHSS occurred
in less than 1% of patients (0.8% in both treatment groups),
which is in line with that reported in a similar patient popu-
lation and using a longGnRHagonist designwithGonal-f (Merck
Serono, Germany) as a comparator (Andersen et al., 2006;
Olivennes et al., 2009; Schats et al., 2000) Sensitivity analy-
sis revealed a high AMH level (cut-off level ≥ 24 pmol/L) to
be related to the OHSS rate. Taking into consideration AMH
levels in both treatment groups, an ancillary analysis re-
vealed the same overall (mild, moderate, severe) OHSS rate
of 2.4% (with 0.8% of the clinical relevant severe form) in both
groups.
At the time the study was designed, AMH was still not fully
acknowledged to be an important, response-predictive clini-
cal parameter. Therefore, it was not included as a stratiﬁ-
cation factor in the study design. As the blood sample was
measured after the study was ﬁnished, the investigators did
not know the AMH level at the time the patient was random-
ized and consequently the start of the FSH treatment. These
ﬁndings, however, support the current view that stratiﬁca-
tion for AMH as an important indicator of ovarian response
in clinical trials is necessary (La Marca and Sunkary, 2013;
Nelson et al., 2012).
The EMA approved Bemfola (Finox AG, Switzerland) on the
basis of these study results, showing that Bemfola (Finox AG,
Switzerland) meets the efﬁcacy and safety requirements as
a FSH product used in IVF treatments. As biologics, includ-
ing biosimilars, are biological products recovered by recom-
binant methods from human or animal cell-lines, the
evaluation of the glycosylation pattern, which has been sug-
gested as the main reason for adverse events, is of particu-
lar interest to health authorities, healthcare providers and
patients. The similar safety results of Study FIN3001, coupled
with the comparable physico-chemical proﬁles of Bemfola
(Finox AG, Switzerland) and Gonal-f (Merck Serono, Germany),
indicate that possible differences in glycosylation pattern
between the two molecules have no clinical consequences.
The cohort size of the study was deﬁned on the basis of the
primary end-point of oocytes retrieved, and thus too small
to detect a signiﬁcant difference in any secondary end-
points, such as pregnancy, and hence further studies are war-
ranted to assess these as primary end-points.
The ﬁxed FSH-dose protocol used has strengths but also
has limitations. The objective of this study was to show a true
comparison of primary end-points. The ﬁxed-dose protocol
supports this approach, as FSH stimulation is less prone to
centre practices, as they might be if dose adaptations had been
permitted. The limitation of such a design, however, is that
optimization of the FSH dose in the case of unexpected low
response was not possible. In this respect, the objective of
the clinical study does not correspond completely to the usual
objectives of clinical practice.
In conclusion, the demonstrated clinical equivalence
of Bemfola (Finox AG, Switzerland) to the reference
comparator Gonal-f (Merck Serono, Germany) in this clini-
cal trial suggests that Bemfola (Finox AG, Switzerland) as
the ﬁrst FSH-biosimilar on the market may be a viable
and familiar alternative to Gonal-f (Merck Serono,
Germany).
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